GoAI
Get started
IceCure Medical Ltd logo

IceCure Medical Ltd

ICCM

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$2.43

−$0.02 · -0.82%

Aug 21, 4:00 PM ET

Pre-market

$2.40

−$0.03 · -1.23%

Aug 24, 6:15 AM ET

ICCM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

52

Fair Value

Momentum

16

Strong Down

Sentiment

42

Mixed

Risk resilience

30

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
IL
CEO
Eyal Shamir
Listed since
Aug 26, 2021
Employees
68

Market position

Day range

Current $2.43

52-week range

Current $2.43

Open
$2.49
Previous close
$2.45
Volume
107.49K
0.03× average
Average volume
3.38M
Average daily volume
Market cap
5.47M USD
Beta
0.47
Market reference 1
50-day average
$3.7883
-35.86% below average
200-day average
$12.5375
-80.62% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
30.1M USD
P/E (TTM)
-0.36×
P/B (TTM)
0.63×
P/S (TTM)
1.39×
EV / EBITDA
-2.03×
Earnings yield
-38.82%
Free cash flow yield
-37.67%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
36.10%
Operating margin
-556.35%
Net margin
-427.67%
Return on equity
-166.36%
Return on assets
-108.42%
Return on invested capital
-162.86%

Financial health

Debt / equity
0.01×
Current ratio
2.61×
Altman Z-score
-11.81
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends113%-128%-369%-611%Gross margin, FY2021: 53.04%Gross margin, FY2022: 46.84%Gross margin, FY2023: 40.26%Gross margin, FY2024: 44.09%Gross margin, FY2025: 36.28%Operating margin, FY2021: -234.99%Operating margin, FY2022: -542.59%Operating margin, FY2023: -482.38%Operating margin, FY2024: -476.94%Operating margin, FY2025: -446.70%Net margin, FY2021: -239.13%Net margin, FY2022: -550.34%Net margin, FY2023: -453.76%Net margin, FY2024: -465.45%Net margin, FY2025: -445.61%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 53.04%. Gross margin FY2022 46.84%. Gross margin FY2023 40.26%. Gross margin FY2024 44.09%. Gross margin FY2025 36.28%. Operating margin FY2021 -234.99%. Operating margin FY2022 -542.59%. Operating margin FY2023 -482.38%. Operating margin FY2024 -476.94%. Operating margin FY2025 -446.70%. Net margin FY2021 -239.13%. Net margin FY2022 -550.34%. Net margin FY2023 -453.76%. Net margin FY2024 -465.45%. Net margin FY2025 -445.61%.

Income trends

Revenue

3.38M USD+2.67%

Operating income

−15.09M USD+3.84%

Net income

−15.06M USD+1.70%
Income trends across reported periods6.25M USD−2.2M USD−10.64M USD−19.09M USDRevenue, FY2021: 4.14M USDRevenue, FY2022: 3.09M USDRevenue, FY2023: 3.23M USDRevenue, FY2024: 3.29M USDRevenue, FY2025: 3.38M USDOperating income, FY2021: −9.72M USDOperating income, FY2022: −16.74M USDOperating income, FY2023: −15.58M USDOperating income, FY2024: −15.7M USDOperating income, FY2025: −15.09M USDNet income, FY2021: −9.9M USDNet income, FY2022: −16.98M USDNet income, FY2023: −14.65M USDNet income, FY2024: −15.32M USDNet income, FY2025: −15.06M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.14M USD. Revenue FY2022 3.09M USD. Revenue FY2023 3.23M USD. Revenue FY2024 3.29M USD. Revenue FY2025 3.38M USD. Operating income FY2021 −9.72M USD. Operating income FY2022 −16.74M USD. Operating income FY2023 −15.58M USD. Operating income FY2024 −15.7M USD. Operating income FY2025 −15.09M USD. Net income FY2021 −9.9M USD. Net income FY2022 −16.98M USD. Net income FY2023 −14.65M USD. Net income FY2024 −15.32M USD. Net income FY2025 −15.06M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue3.38M USD3.29M USD3.23M USD3.09M USD4.14M USD
Cost of goods sold2.15M USD1.84M USD1.93M USD1.64M USD1.94M USD
Gross profit1.23M USD1.45M USD1.3M USD1.45M USD2.2M USD
Research and development7.43M USD7.1M USD8.27M USD9.12M USD5.88M USD
Selling, general, and administrative8.89M USD10.05M USD8.6M USD9.06M USD6.04M USD
Operating expenses16.32M USD17.15M USD16.88M USD18.18M USD11.92M USD
Interest income37K USD378K USD924K USD——
Depreciation and amortization295K USD332K USD323K USD——
Operating income−15.09M USD−15.7M USD−15.58M USD−16.74M USD−9.72M USD
Net income−15.06M USD−15.32M USD−14.65M USD−16.98M USD−9.9M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
18%
2 beats, 8 misses, 1 met estimate
Average EPS surprise
-283.36%
11 comparable reports
Latest EPS result
-1.54
Estimate -1.52 · Miss by 1.32%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.78-1.36-1.94-2.52Q2 '25MissQ2 '25BeatQ3 '25MetQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q2 2025, reported Apr 2, 2025: actual -2.35, estimate -2.21, surprise -6.67%, Miss. Q2 2025, reported May 28, 2025: actual -1.8, estimate -2.4, surprise +25.00%, Beat. Q3 2025, reported Aug 13, 2025: actual -1.8, estimate -1.8, surprise 0.00%, Met estimate. Q4 2025, reported Nov 19, 2025: actual -1.8, estimate -1.5, surprise -20.00%, Miss. Q1 2026, reported Mar 17, 2026: actual -1.8, estimate -1.2, surprise -50.00%, Miss. Q2 2026, reported May 12, 2026: actual -1.8, estimate -0.9, surprise -100.00%, Miss. Q3 2026, reported Aug 12, 2026: actual -1.54, estimate -1.52, surprise -1.32%, Miss. Q4 2026, reported Nov 18, 2026: actual —, estimate -1.16, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.52M1.17M808.77K450.97KQ2 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MetQ2 '26MissQ3 '26MissQ4 '26Estimate
Q2 2025, reported Apr 2, 2025: actual 875K USD, estimate 1.07M USD, surprise -18.03%, Miss. Q2 2025, reported May 28, 2025: actual 725K USD, estimate 750K USD, surprise -3.33%, Miss. Q3 2025, reported Aug 13, 2025: actual 525K USD, estimate 662.5K USD, surprise -20.75%, Miss. Q4 2025, reported Nov 19, 2025: actual 850K USD, estimate 714K USD, surprise +19.05%, Beat. Q1 2026, reported Mar 17, 2026: actual 1.3M USD, estimate 1.3M USD, surprise 0.00%, Met estimate. Q2 2026, reported May 12, 2026: actual 911K USD, estimate 1.34M USD, surprise -32.23%, Miss. Q3 2026, reported Aug 12, 2026: actual 907K USD, estimate 1.45M USD, surprise -37.46%, Miss. Q4 2026, reported Nov 18, 2026: actual —, estimate 876.5K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$1.00

58.85% downside
Past 12 months12-month forecastHigh $1.00Average $1.00Low $1.00

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions
Maxim GroupmaintainBuy
Alliance Global PartnersmaintainBuy

ICCM news

prnewswire.com

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

Patients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown, TN CAESAREA, Israel, Aug.…

Read source
prnewswire.com

IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation

New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second…

Read source
seekingalpha.com

IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript

IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript

Read source
prnewswire.com

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("FDA") clearance,…

Read source
prnewswire.com

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

Adventist Health Glendale is the first site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval The site will be led by breast surgeon, Dr. Dennis Holmes, MD, FACS, a…

Read source
prnewswire.com

IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026

CAESAREA, Israel, Aug. 5, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing…

Read source

Corporate actions

Corporate action history

Stock split

Effective Jun 4, 2026

1:30

Stock split

Effective Aug 9, 2021

1:8

ICCM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research ICCM

research.disclaimer